OmniAb, Inc. (NasdaqGM: OABI)
Health Care · Life Sciences Tools & Services · US
$4.33
+28.11% today · +68.2% 1Y
OmniAb, Inc. (NasdaqGM: OABI) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $491.42M and employs 89 people.
Over the last twelve months the share price has gained 68.2%, trading between 1.30 and 3.44.
Tweenvest scores OmniAb, Inc. across four factors: quality 43/100, value 55/100, growth 0/100. Its strongest factor is value.
OABI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $491.42M
- Revenue (TTM)
- $38.46M
- P/E
- —
- EPS
- -0.35
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- $3.44
- 52-week low
- $1.30
- Avg volume (3M)
- —
- Shares outstanding
- 145.39M
- Employees
- 89
- Next earnings
- —
About OmniAb, Inc.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
- Founded
- 2012
- Listed since
- Sep 30, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $629.27 | +0.27% |
| Danaher CorporationNYSE: DHR | $153.85B | $218.85 | +1.36% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF590.20 | -0.34% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $159.00 | +1.73% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.82 | +1.47% |
| Waters CorporationNYSE: WAT | $40.35B | $410.70 | +1.49% |
Figures last refreshed Aug 18, 2026.